Endothelin receptor antagonists and cardiovascular diseases of aging

Drugs and Aging

Volumn 18, Issue 6, 2001, Pages 425-440

  Love, M P ^a   McMurray, J J V ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b Clin Res Initiative Heart Failure   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; PEPTIDE DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT INDICATION;

EID: 0035005338     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118060-00005     Document Type: Review

References (157)

1. Cardiovascular medicine at the turn of the millenium: Triumphs, concerns and opportunities
2. Heart disease, cancer, and stroke mortality trends and their interrelations: An international perspective
3. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
4. The clinical potential of endothelin receptor antagonists in cardiovascular medicine
5. Endothelin antagonists
6. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators
7. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic chronic heart failure
8. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
9. The endothelin family of peptides: Local hormones with diverse roles in health and disease?
10. Endothelin in chronic heart failure; current position and future prospects
11. ECE-I: A membrane bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1
12. Human endothelin converting enzyme (ECE-I): Three isoforms with distinct subcellular localizations
13. Cloning and expression of a cDNA encoding an endothelin receptor
14. Cloning of a cDNA encoding a nonisopeptide selective subtype of the endothelin receptor
15. Endothelin is a potent long-lasting vasoconstrictor in men
16. Pharmacology of endothelin-1 in vivo in humans
17. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers
18. Endothelin receptors mediating functional responses in human small arteries and veins
19. A receptors in humans?
20. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
21. Endothelin B receptor mediated contraction in human pulmonary resistance arteries
22. B receptors mediate contraction to endothelin-1 in human blood vessels
23. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
24. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
25. B receptors in rats
26. Contribution of endogenous generation of endothelin-1 to basal vascular tone
27. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
28. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells
29. Endothelin is a potent mitogen for rat vascular smooth muscle cells
30. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium
31. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression
32. B receptor blockade
33. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes
34. B receptor antagonist
35. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium
36. Inotropic effects of endothelin-1: Interaction with molsidomine and with BQ 610
37. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide
38. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation
39. Cardiopulmonary effects of endothelin-1 in man
40. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart
41. Endothelins in the kidney: Pysiology and pathophysiology
42. Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology
43. Endothelin enhances adrenergic vasoconstriction in perfused rat mesenteric arteries
44. Mechanisms of the effects of endothelin on responses to noradrenaline and sympathetic nerve stimulation
45. Direct and sympathetically mediated venoconstriction in essential hypertension: Enhanced responses to endothelin-1
46. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells
47. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells
48. Cardiorenal actions of endothelin part 1: Effects of converting enzyme inhibition
49. Endothelin1 augments pressor response to angiotensin II infusion in rats
50. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries
51. Is endothelin involved in the pathogenesis of hypertension?
52. Three cases of malignant hypertension: The roles of endothelin-1 and the renin-angiotensin-aldosterone systems
53. Polar secretion of endothelin-1 by cultured endothelial cells
54. Characteristics of pressure response to endothelin in spontaneously hypertensive and Wistar-Kyoto rats
55. Experimental hypertension produces diverse changes in the regional vascular responses to endothelin-1 in the rabbit and the rat
56. Role of endothelin in the increased vascular tone of patients with essential hypertension
57. Endothelin sensitivity and receptor binding in the aorta of spontaneously hypertensive rats
58. Endothelin-1 in hypertensive resistance arteries: Intraluminal and extraluminal dysfunction
59. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients
60. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension
61. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertension model
62. BQ-123, a selective endothelin subtype-A receptor antagonist, lowers blood pressure in different rat models of hypertension
63. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist
64. A-receptor antagonist
65. A-receptor blockade in angiotensin II-induced hypertension
66. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade
67. A-receptor blockade
68. Effect of a non selective endothelin antagonist on vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats: Evidence for a role of endothelin in vascular hypertrophy
69. Respective role of humoral factors and blood pressure in cardiac remodelling of DOCA hypertensive rats
70. Effects of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats
71. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats
72. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats
73. Small artery structure in hypertension: Dual process of remodelling and growth
74. A-receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats
75. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats
76. ETA-receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
77. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension
78. Role of endothelin in mediating the attenuated renal hemodynamics in Dahl salt-sensitive hypertension
79. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: Comparison with angiotensin-converting enzyme inhibition and calcium antagonism
80. Preglomerular sudanophilia in L-NAME hypertensive rats: Involvement of endothelin
81. Effects of selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hypertensive rats
82. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
83. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium
84. 2 production in human alveolar macrophages
85. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop
86. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
87. Increased plasma immunoreactive endothelin-1 concentration in hypercholesterolemic rats
88. Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolaemia without evidence of atherosclerosis
89. Circulating endothelin in acute ischaemic syndromes
90. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina
91. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction
92. Raised plasma endothelin in unstablo angina and non-Q wave myocardial infarction: Relation to cardiovascular outcome
93. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol
94. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
95. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolaemia
96. The pathogenesis of coronary artery disease and the acute coronary syndromes
97. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolaemia in vitro
98. Chronic endothelin A receptor antagonism improves vasorelaxations to natriuretic peptides in atherosclerosis
99. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone
100. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease
101. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats
102. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion
103. B receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats
104. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat
105. Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice
106. Endothelin and restenosis
107. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo
108. Orally active endothelin receptor antagonist BMS-182874 suppresses neo-intimal development in balloon-injured rat carotid arteries
109. B receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty
110. Increased plasma endothelin-1 levels in acute ischaemic stroke
111. Endothelin in cerebrospinal fluid and plasma of patients in the early stage of ischemic stroke
112. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: A diffusion and perfusion MRI study
113. The endothelin receptor antagonist SB217242 reduces cerebral focal ischemic brain injury
114. Endothelin: New discoveries and rapid progress in the clinic
115. Plasma endothelin in chronic heart failure
116. Increased plasma concentrations of endothelin in chronic heart failure in humans
117. Plasma endothelin and pulmonary pressures in patients with congestive heart failure
118. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
119. Plasma endothelin in congestive heart failure: A predictor of cardiac death?
120. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
121. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
122. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure
123. Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction
124. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure
125. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure
126. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure
127. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure
128. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs
129. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothelin A receptor antagonism
130. Inhibition of myocardial endothelin pathway improves long term survival in heart failure
131. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits
132. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling
133. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: Possible involvement of myocardial endothelin system in ventricular remodeling
134. A receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
135. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure
136. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats
137. Chronic endothelin-1 blockade preserves myocardial contractility in dilated cardiomyopathy
138. Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure
139. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure
140. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure
141. Chronic oral endothelin type A receptor antagonism in experimental heart failure
142. ET receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats
143. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothelin-1 production in the heart and beneficial effect of endothetin-A receptor antagonist on survival and cardiac function
144. Chronic endothelin blockade in dogs with pacing-induced heart failure: Possible modulation of sympathoexcitation
145. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
146. A-receptor antagonist, in chronic heart failure
147. Acute ETA receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure
148. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure
149. Improved hemodynamics with the ETA selective receptor antagonist BMS-193884 in patients with heart failure
150. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure
151. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure
152. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans
153. Multi-centre, double-blind, placebo-controlled study of long-term endothelin blockade with boseman in chronic heart failure: Results of the Reach trail
154. Endothelin receptor antagonism in patients with chronic heart failure
155. Endothelins are potent vasoconstrictors, and much more besides
156. Inhibition of big ET-1 induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11
157. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: A placebo-controlled study